Madrigal Pharmaceuticals Reports Promising Two-Year Results for MASH Therapy
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced positive two-year results from the Phase 3 MAESTRO-NAFLD-1 trial, demonstrating the potential of Rezdiffra (resmetirom) to significantly reduce liver stiffness in …
Madrigal Pharmaceuticals Reports Promising Two-Year Results for MASH Therapy Read More